GSK’s Witty Looks To Biotech Model In R&D Retool; Mini Labs Will Bid For Project Funding
This article was originally published in The Pink Sheet Daily
Executive Summary
Planned units include five to 80 scientists, operate within the CEDDs program.
You may also be interested in...
How GSK Is Driving Early Stage Research In Its DPUs
Most of GlaxoSmithKline's early stage research organizations, discovery performance units, survive a three-year review cycle, with co-localization, monetary incentives and career support leading a change of culture.
Incentives And Less Fear Of Failure: How GSK Is Driving Early-Stage Research In Its DPUs
Most of GlaxoSmithKline's early-stage research organizations, discovery performance units, survive a three-year review cycle, with co-localization, monetary incentives and career support leading a change of culture.
Glaxo's Strategy For Drug Performance Units Is Showing Promise, Slaoui Says
R&D Chairman Moncef Slaoui provides update on drug performance units one year out at Windhover's Pharmaceutical Strategic Alliance Conference.